News

Vacancy – Clinical Scientist

NewGene are seeking to expand and strengthen the laboratory team through the appointment of a HCPC Registered Clinical Scientist. Potential applicants are encouraged to contact Dr Angela Silmon, Chief Executive, for more information regarding this exciting opportunity – telephone 0191 242 1923 or email [email protected]

Application information is available here at the NHS jobs site.

Click here to download a more detailed job description. The closing date for applications is 20 January 2017.

Come and meet NewGene at:

The British Society for Genetic Medicine 2016 Annual Meeting
22nd September, Royal College of Physicians, London

The Biomarkers Congress 2017
21-22nd February, Manchester

Strengthening the Business Development Team

NewGene are delighted to announce the appointment of Dr Ben Chaffey as Business Development Manager, to support the expansion of the contract clinical and pre-clinical research work the company undertakes alongside its core clinical diagnostics services. Ben has a broad technical background with marketing and business development experience in industry working for companies such as HBI Ltd and Biosignatures.

Industry Focus:

Biomarkers in Personalised Medicine: discovery and delivery

Writing in The Biochemist, NewGene contribute to the conversation on the challenges of biomarker discovery and implementation in a clinical setting.

Click here to view a pdf of the article.

The great success of NewGene User Group Meetings

Over the course of the spring months NewGene have held a number of user group meetings, bringing together our customers, regional clinical experts and the NewGene team to discuss the state of the art in each clinical field and to define how to implement service development and best practice to the processes in our region.

• EGFR User group meeting, sponsored by Astra Zeneca
• RAS User group meeting, sponsored by Merck Serono
• Haematology User group meeting, sponsored by NewGene

Bringing state of the art tumour profiling to the region

NewGene are part of an effort to deliver a Cancer Molecular Pathology Hub

In many areas of cancer we are seeing advances that allow the delivery of personalised or precision medicine with novel agents specifically targeted at the genetic changes causing disease. Investment in a Cancer Molecular Pathology Hub and harnessing the expertise in next generation sequencing at NewGene will allow the Sir Bobby Robson Cancer Trials Research Centre to continue its leading role in the development of new cancer treatments.

From April 2016 patients referred to the trials unit will be offered the opportunity to have their tumours profiled to identify any mutations in a panel of genes known to be associated with cancer. This will support signposting of the patients to appropriate clinical trials and add to the knowledge base on the causes of cancer.